|
Childhood Acute Lymphoblastic Leukemia
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
No significant difference was found between the fast-acetylator incidence of NAT2 haplotype and the onset risk of acute lymphoblastic leukemia (ALL, OR=0.70, 95% CI=0.45-1.08) or acute myeloid leukemia (AML, OR=0.79, 95% CI=0.46-1.47).
|
31773677 |
2019 |
|
Acute lymphocytic leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
No significant difference was found between the fast-acetylator incidence of NAT2 haplotype and the onset risk of acute lymphoblastic leukemia (ALL, OR=0.70, 95% CI=0.45-1.08) or acute myeloid leukemia (AML, OR=0.79, 95% CI=0.46-1.47).
|
31773677 |
2019 |
|
Adult Acute Lymphocytic Leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
No significant difference was found between the fast-acetylator incidence of NAT2 haplotype and the onset risk of acute lymphoblastic leukemia (ALL, OR=0.70, 95% CI=0.45-1.08) or acute myeloid leukemia (AML, OR=0.79, 95% CI=0.46-1.47).
|
31773677 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
No significant difference was found between the fast-acetylator incidence of NAT2 haplotype and the onset risk of acute lymphoblastic leukemia (ALL, OR=0.70, 95% CI=0.45-1.08) or acute myeloid leukemia (AML, OR=0.79, 95% CI=0.46-1.47).
|
31773677 |
2019 |
|
Acute leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Only cohort studies and case-control studies which provided odds ratio (OR) and 95% confidence interval (CI) of the correlation between NAT2 polymorphisms and susceptibility of acute leukemia up to December 1st, 2018 were enrolled.
|
31773677 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study suggests that NAT2*13A and NAT2*6B variant alleles are risk factors for developing hepatotoxicity, and PLWHA with genotypes NAT2*13A/NAT2*13A and NAT2*13A/NAT2*6B should be targeted for specific care to reduce the risk of hepatotoxicity during treatment for tuberculosis.
|
31734174 |
2020 |
|
hiv-infection/aids
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil.
|
31734174 |
2020 |
|
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Subset analysis of NAT2 acetylator status and severity grade confirmed these results in AT-DILI patients with more severe disease whereas fast and intermediate acetylator phenotypes were associated with a decreased AT-DILI risk.
|
31699005 |
2019 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> NAT2 slow acetylator was significantly associated with AT-DILI risk (p = 2.7 × 10<sup>-7</sup>; odds ratio [95% CI] = 3.64 [2.21-6.00]).
|
31699005 |
2019 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To better understand the role of NAT2 genetic polymorphism in ABP- and AF-induced mutagenesis and DNA damage, nucleotide excision repair-deficient (UV5) Chinese hamster ovary (CHO) cells were stably transfected with human CYP1A2 and either NAT2*4 (rapid acetylator) or NAT2*5B (slow acetylator) alleles.
|
31490564 |
2020 |
|
NAT2 polymorphism
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the NAT2 polymorphism in the Buginese ethnic group of Indonesia to determine the frequency of NAT2 alleles in this population.
|
31332782 |
2019 |
|
Coronary heart disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our study suggests that the risk of CHDs associated with maternal NAT2 gene polymorphisms is potentiated by PAHs exposure.
|
31254350 |
2019 |
|
Congenital heart disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The present study was designed to investigate whether maternal NAT2 genetic polymorphisms are associated with fetal susceptibility to congenital heart diseases (CHDs) and to assess whether the risk is modified by polycyclic aromatic hydrocarbons (PAHs) exposure.
|
31254350 |
2019 |
|
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population.
|
31245212 |
2019 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conclusion In the present study, the slow acetylators of the NAT2 genotype did not contribute to the elevated risk of ATDIH development in tuberculosis patients.
|
31245212 |
2019 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the genotypic distribution of variants of slow-acetylator genotypes (NAT2*6/7, NAT2*5/7, and NAT2*5/6) was also not significantly different in ATDIH.
|
31245212 |
2019 |
|
Caffeine related disorders
|
0.040 |
Biomarker
|
group |
BEFREE |
Enzyme phenotyping was assessed in saliva and urine using caffeine metabolite ratios as follows: CYP1A2: 17X/137Χ (saliva) and CYP1A2: (AFMU+1U+1X)/17U, CYP2A6: 17U/(17U + 17X), XO: 1U/(1U+1X) and NAT2: AFMU/(AFMU+1U+1X) (urine).
|
31082462 |
2019 |
|
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population.
|
31066138 |
2019 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population.
|
31066138 |
2019 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The slow acetylator status of N-acetyl transferase 2 (NAT2) is a well-established risk factor for ATDH.
|
31066138 |
2019 |
|
Acute leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between NAT2 polymorphisms and AL risk.
|
30896661 |
2019 |
|
Age related macular degeneration
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Sixty-eight patients presenting pigment epithelial detachments resistant to ranibizumab (issued from ARI2 study, register number NCT02157077 on clinicaltrials.gov) were compared with two series of patients derived from previously published clinical studies, presenting neovascular AMD (NAT2 study n = 300 and PHRC study n = 1,127), and with healthy controls (n = 441).
|
30681643 |
2020 |
|
Glycogen storage disease type II
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sixty-eight patients presenting pigment epithelial detachments resistant to ranibizumab (issued from ARI2 study, register number NCT02157077 on clinicaltrials.gov) were compared with two series of patients derived from previously published clinical studies, presenting neovascular AMD (NAT2 study n = 300 and PHRC study n = 1,127), and with healthy controls (n = 441).
|
30681643 |
2020 |
|
Ulcerative Colitis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The most important outcome of this study is that for the first time we demonstrated the simultaneous presence of TMDR1, A CYP2D6*4 and A NAT2*7 alleles robustly increased the risk of developing UC by 3.49-fold.
|
30551694 |
2018 |
|
Withdrawal Symptoms
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Prolonged clonazepam-induced withdrawal symptoms in an NAT2 ultraslow acetylator.
|
30520338 |
2019 |